statistiche ricercatore

GROSSI, FRANCESCO

Distribuzione geografica

Continente	#
EU - Europa	4.935
NA - Nord America	4.411
AS - Asia	2.919
SA - Sud America	529
AF - Africa	51
Continente sconosciuto - Info sul continente non disponibili	4
OC - Oceania	4
Totale	12.853

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	4.311
IT - Italia	3.312
SG - Singapore	1.627
HK - Hong Kong	692
IE - Irlanda	571
BR - Brasile	460
CN - Cina	292
GB - Regno Unito	257
RU - Federazione Russa	237
SE - Svezia	205
DE - Germania	136
VN - Vietnam	88
IN - India	61
CA - Canada	47
FI - Finlandia	47
MX - Messico	40
JP - Giappone	34
PL - Polonia	30
AR - Argentina	29
UA - Ucraina	28
AT - Austria	26
TR - Turchia	25
ZA - Sudafrica	24
BD - Bangladesh	23
ES - Italia	19
IQ - Iraq	19
NL - Olanda	19
FR - Francia	15
UZ - Uzbekistan	12
BE - Belgio	10
LT - Lituania	9
EC - Ecuador	8
CL - Cile	7
SA - Arabia Saudita	7
PY - Paraguay	6
VE - Venezuela	6
EG - Egitto	5
MA - Marocco	5
PK - Pakistan	5
TN - Tunisia	5
UY - Uruguay	5
AE - Emirati Arabi Uniti	4
EU - Europa	4
ID - Indonesia	4
JO - Giordania	4
KE - Kenya	4
KZ - Kazakistan	4
PA - Panama	4
PE - Perù	4
CH - Svizzera	3
CO - Colombia	3
IL - Israele	3
NG - Nigeria	3
TT - Trinidad e Tobago	3
AL - Albania	2
AU - Australia	2
AZ - Azerbaigian	2
BG - Bulgaria	2
DZ - Algeria	2
NI - Nicaragua	2
PS - Palestinian Territory	2
PT - Portogallo	2
RS - Serbia	2
TH - Thailandia	2
AO - Angola	1
BB - Barbados	1
BO - Bolivia	1
CZ - Repubblica Ceca	1
DM - Dominica	1
DO - Repubblica Dominicana	1
ET - Etiopia	1
GA - Gabon	1
GE - Georgia	1
JM - Giamaica	1
KG - Kirghizistan	1
KI - Kiribati	1
KW - Kuwait	1
MD - Moldavia	1
NO - Norvegia	1
NP - Nepal	1
OM - Oman	1
PH - Filippine	1
QA - Qatar	1
SY - Repubblica araba siriana	1
TO - Tonga	1
TW - Taiwan	1
Totale	12.853

Salva come PNG Salva come JPEG

Città	#
Milan	2.457
Singapore	840
Hong Kong	685
Dublin	571
Dallas	472
Princeton	435
Ashburn	376
Fairfield	300
Boardman	263
Rome	222
Wilmington	199
Beijing	161
Nyköping	160
Chandler	131
Chicago	126
San Diego	115
Woodbridge	111
The Dalles	109
London	108
Seattle	99
Los Angeles	92
Houston	91
Ogden	86
Cambridge	75
Ann Arbor	56
Santa Clara	56
New York	50
São Paulo	48
Como	45
Munich	34
Ho Chi Minh City	32
Warsaw	28
Tokyo	27
Hanoi	23
Nuremberg	23
Pune	23
Helsinki	22
Norwalk	22
Denver	20
Mexico City	20
Salt Lake City	20
Orem	19
Tampa	19
Brooklyn	18
Chiswick	18
San Francisco	17
Atlanta	16
Kilburn	16
Stockholm	15
Turku	15
Vienna	15
Chennai	14
Johannesburg	14
Montreal	14
Rio de Janeiro	14
Toronto	14
Council Bluffs	13
Frankfurt am Main	13
Jacksonville	13
Phoenix	13
Redmond	13
Washington	13
Boston	11
Buffalo	11
Amsterdam	10
Belo Horizonte	10
Poplar	10
Brussels	9
Düsseldorf	9
Elk Grove Village	9
Falkenstein	9
Tashkent	9
Genoa	8
Prescot	8
Saronno	8
Sterling	8
Acton	7
Ankara	7
Baghdad	7
Curitiba	7
Detroit	7
New Bedfont	7
Turin	7
Assago	6
Brasília	6
Charlotte	6
Erbil	6
Goiânia	6
Guangzhou	6
Hounslow	6
Juiz de Fora	6
Kowloon	6
Lancaster	6
Miami	6
Norwich	6
Porto Alegre	6
Shanghai	6
Southwark	6
Berlin	5
Dhaka	5
Totale	9.427

Salva come PNG Salva come JPEG

Nome	#
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin	160
Analysis of K-ras, p53, bcl-2 and Rb expression in non-small cell lung cancer cell lines.	143
Afatinib for the treatment of non-small cell lung cancer	119
30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)	102
Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis	92
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study	92
Afatinib for the treatment of advanced non-small-cell lung cancer	91
A review of clinical practice guidelines and treatment recommendations for cancer care in the COVID-19 pandemic	91
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy	89
Advances in treatment of mesothelioma	87
A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019)	86
DISRUPT: a randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer	85
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer	82
Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy	81
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation	79
An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy	77
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation	76
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer	76
Adjuvant treatment for patients with incidentally resected limited disease small cell lung cancer-a retrospective study	76
Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines	76
Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial	76
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low cost chemotherapy for advanced colorectal cancer	74
Adjuvant chemotherapy for non-small cell lung cancer: Ready for clinical practice?	74
Novel treatment strategies for early-stage lung cancer: The oncologist’s perspective	74
Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers	72
Immune checkpoint inhibitors for treatment of small-cell lung cancer: a systematic review and meta-analysis	72
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes	71
A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer	71
Liquid biopsy in non-small cell lung cancer: highlights and challenges	71
Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects	70
Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds	70
Vinflunine for the treatment of non-small cell lung cancer	69
Oral Vinorelbine Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-Line Treatment for Patients with Advanced non- Squamous non- Small Cell Lung Cancer: a Cost Minimization Analysis in Twelve European Countries	69
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer	69
Hematopoietic growth factors in lung cancer	69
Alternating bolus and continuous infusion 5-fluorouracil: A strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients	69
Adjuvant pembrolizumab for melanoma: update from the EORTC 1325-MG/KEYNOTE-054 trial	69
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer	69
Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial	68
Pleural and peripheral lung lesions: comparison of US- and CT-guided biopsy	68
Exosomes: a new horizon in lung cancer	68
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial	67
Introduction of the beta isozyme of protein kinase C accelerates induced differentiation of murine erythroleukemia cells	67
Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer	67
PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells	66
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine	66
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy	66
Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial	65
Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab	65
Ramucirumab: preclinical research and clinical development	65
The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib	65
Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib	65
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)	64
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)	64
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition	64
IDH signalling pathway in cholangiocarcinoma: From biological rationale to therapeutic targeting	64
Tumor microenvironment as a potential source of clinical biomarkers in non-small cell lung cancer: can we use enemy territory at our advantage?	63
Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography?	63
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial	63
Update on the treatment of small cell lung cancer (SCLC)	63
Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy	62
Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: A randomized study	62
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study	62
NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer	61
Impact of low-dose computed tomography screening on lung cancer mortality among asbestos-exposed workers	61
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study	61
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis	61
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study	61
Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer	61
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer	61
Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases	60
A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer	60
Oral vinorelbine plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of advanced non-squamous non-small-cell lung cancer: cost minimization analysis in 12 European countries	60
Looking for results in non-small-cell lung cancer: is bio-chemotherapy the right answer?	60
Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors	60
IL-12 Can Target Human Lung Adenocarcinoma Cells and Normal Bronchial Epithelial Cells Surrounding Tumor Lesions	60
Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients	59
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial	59
Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma	59
COVID-19 vaccination in patients with classic Kaposi’s sarcoma	59
Management of malignant pleural effusions	59
Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer.	58
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy	58
The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer	58
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG	58
Use of nivolumab in elderly patients with advanced squamous non–small-cell lung cancer: results from the Italian cohort of an expanded access programme	58
Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer	58
Successful treatment of lung adenocarcinoma with gefitinib based on EGFR gene amplification	57
Systemic drug therapy of malignant pleural mesothelioma.	57
Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in Italy	57
Targeting kras in solid tumors: Current challenges and future opportunities of novel kras inhibitors	57
Comparison between 18f-fdg pet-based and ct-based criteria in non-small cell lung cancer patients treated with nivolumab	57
Letter of response to comments on: Developing a risk assessment score for patients with cancer during COVID-19 pandemic: A war on two fronts	57
Managing patients with lung cancer - Common international guidelines must be developed	56
Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001)	56
New perspectives for the pharmacological and biological therapy of small cell lung cancer	56
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2)	56
Impact of bmi on survival outcomes of immunotherapy in solid tumors: A systematic review	56
Triage process for the assessment of coronavirus disease 2019-positive patients with cancer: The ONCOVID prospective study	56
The clinical management of early and advanced colorectal cancer	55
Totale	6.923

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	120.403
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	120.403

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	31	0	0	0	0	0	10	0	4	4	3	2	8
2021/2022	1.833	0	5	1	0	430	190	192	151	232	186	105	341
2022/2023	1.155	225	49	70	40	78	310	4	69	84	176	16	34
2023/2024	3.882	483	689	646	787	905	116	26	52	146	12	3	17
2024/2025	3.119	17	29	584	41	37	221	101	99	499	220	208	1.063
2025/2026	3.228	393	647	495	975	548	170	0	0	0	0	0	0
Totale													13.389